A late-stage biotechnology business called Novavax, Inc. (Nasdaq: NVAX) works to advance global health by discovering, creating, and commercializing novel vaccines to fend off deadly infectious illnesses.
Clinical studies are being conducted for NVX-CoV2373, a vaccine candidate by Novavax against COVID-19’s causative virus, SARS-CoV-2. In the Phase 1 section of the Phase 1/2 clinical study, NVXCoV2373 was usually well tolerated and produced significant antibody responses that were quantitatively greater than those found in human convalescent sera. In its critical Phase 3 clinical study in older individuals, NanoFluTM, its quadrivalent influenza nanoparticle vaccine, achieved all major goals. Both vaccination candidates use Novavax’s patented Matrix-MTM adjuvant, which is based on saponins and stimulates the production of large quantities of neutralizing antibodies. A renowned producer of recombinant vaccines, Novavax’s
